Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
17
03
2021
accepted:
24
03
2022
pubmed:
5
5
2022
medline:
28
5
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies
Identifiants
pubmed: 35508656
doi: 10.1038/s41586-022-04685-2
pii: 10.1038/s41586-022-04685-2
pmc: PMC9132770
doi:
Substances chimiques
Antineoplastic Agents
0
Quinolines
0
N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine
19DG7G1U5Q
Adenosine
K72T3FS567
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
741-746Subventions
Organisme : Cancer Research UK
ID : 25722
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : P01 DK046763
Pays : United States
Organisme : NIH HHS
ID : S10 OD025052
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR027366
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014).
doi: 10.1056/NEJMoa1315226
Gopal, A. K. et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 997–1007 (2014).
doi: 10.1056/NEJMoa1314583
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 20, 741–769 (2021).
doi: 10.1038/s41573-021-00209-1
Ali, K. et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014).
doi: 10.1038/nature13444
Lim, E. L. et al. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. JCI Insight 3, e120626 (2018).
doi: 10.1172/jci.insight.120626
Lampson, B. L. et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128, 195–203 (2016).
doi: 10.1182/blood-2016-03-707133
Lim, E. L. & Okkenhaug, K. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy. Immunology 157, 210–218 (2019).
doi: 10.1111/imm.13082
Chellappa, S. et al. The PI3K p110δ isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function. J. Immunol. 202, 1397–1405 (2019).
doi: 10.4049/jimmunol.1701703
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
doi: 10.1038/s41586-019-1324-y
Khan, O. et al. TOX transcriptionally and epigenetically programs CD8
doi: 10.1038/s41586-019-1325-x
Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269 (2019).
doi: 10.1038/s41586-019-1326-9
Lampson, B. L. & Brown, J. R. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin. Investig. Drugs 26, 1267–1279 (2017).
doi: 10.1080/13543784.2017.1384815
DiSpirito, J. R. et al. Molecular diversification of regulatory T cells in nonlymphoid tissues. Sci. Immunol. 3, eaat5861 (2018).
doi: 10.1126/sciimmunol.aat5861
Miragaia, R. J. et al. Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation. Immunity 50, 493–504.e7 (2019).
doi: 10.1016/j.immuni.2019.01.001
Wing, J. B., Ise, W., Kurosaki, T. & Sakaguchi, S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41, 1013–1025 (2014).
doi: 10.1016/j.immuni.2014.12.006
Ovcinnikovs, V. et al. CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells. Sci. Immunol. 4, eeaw0902 (2019).
doi: 10.1126/sciimmunol.aaw0902
Zhang, N. et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 30, 458–469 (2009).
doi: 10.1016/j.immuni.2008.12.022
Delacher, M. et al. Precursors for nonlymphoid-tissue T
doi: 10.1016/j.immuni.2019.12.002
Whibley, N., Tucci, A. & Powrie, F. Regulatory T cell adaptation in the intestine and skin. Nat. Immunol. 20, 386–396 (2019).
doi: 10.1038/s41590-019-0351-z
Arpaia, N. et al. A distinct function of regulatory T cells in tissue protection. Cell 162, 1078–1089 (2015).
doi: 10.1016/j.cell.2015.08.021
Aaronson, D. S. & Horvath, C. M. A road map for those who don’t know JAK–STAT. Science 296, 1653–1655 (2002).
doi: 10.1126/science.1071545
Hu, X. & Ivashkiv, L. B. Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases. Immunity 31, 539–550 (2009).
doi: 10.1016/j.immuni.2009.09.002
La Manno, G. et al. RNA velocity of single cells. Nature 560, 494–498 (2018).
doi: 10.1038/s41586-018-0414-6
Bergen, V., Lange, M., Peidli, S., Wolf, F. A. & Theis, F. J. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat. Biotechnol. 38, 1408–1414 (2020).
doi: 10.1038/s41587-020-0591-3
L, R. et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 58, 1629–1636 (2009).
doi: 10.1136/gut.2009.182170
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R. & Weaver, C. T. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc. Natl Acad. Sci. USA 112, 7061–7066 (2015).
doi: 10.1073/pnas.1415675112
Feng, T. et al. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J. Immunol. 186, 6313–6318 (2011).
doi: 10.4049/jimmunol.1001454
Denning, T. L. et al. Mouse TCRαβ
doi: 10.4049/jimmunol.178.7.4230
Poussier, P., Ning, T., Banerjee, D. & Julius, M. A unique subset of self-specific intraintestinal T cells maintains gut integrity. J. Exp. Med. 195, 1491–1497 (2002).
doi: 10.1084/jem.20011793
Chaudhry, A. et al. CD4
doi: 10.1126/science.1172702
Ward, M. J. et al. Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head Neck 37, 1002–1013 (2015).
doi: 10.1002/hed.23697
Wood, O. et al. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget 7, 56781–56797 (2016).
doi: 10.18632/oncotarget.10788
Ottensmeier, C. H. et al. Upregulated glucose metabolism correlates inversely with CD8
doi: 10.1158/0008-5472.CAN-15-3121
Lanasa, M. C. et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kδ, in adult patients with relapsed or refractory lymphoid malignancies. Blood 122, 678 (2013).
doi: 10.1182/blood.V122.21.678.678
Vijayanand, P. et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 1410–1422 (2007).
doi: 10.1056/NEJMoa064691
Juneja, V. R. et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J. Exp. Med. 214, 895–904 (2017).
doi: 10.1084/jem.20160801
Patil, V. S. et al. Precursors of human CD4
doi: 10.1126/sciimmunol.aan8664
Finak, G. et al. MAST: A flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).
doi: 10.1186/s13059-015-0844-5